Results 111 to 120 of about 3,679,356 (272)

Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

Nature Communications, 2019
In acute myeloid leukemia, hypomethylating agents decitabine and azacytidine are used interchangeably. Here, the authors show that the major metabolite of decitabine, but not azacytidine, is subject to SAMHD1 inactivation, highlighting SAMHD1 as a ...
Thomas Oellerich, Constanze Schneider, Dominique Thomas, Kirsten M. Knecht, Olga Buzovetsky, Lars Kaderali, Christoph Schliemann, Hanibal Bohnenberger, Linus Angenendt, Wolfgang Hartmann, Eva Wardelmann, Tamara Rothenburger, Sebastian Mohr, Sebastian Scheich, Federico Comoglio, Anne Wilke, Philipp Ströbel, Hubert Serve, Martin Michaelis, Nerea Ferreirós, Gerd Geisslinger, Yong Xiong, Oliver T. Keppler, Jindrich Cinatl   +23 more
doaj   +1 more source

Outcome of therapy-related myeloid neoplasms treated with azacitidine

Journal of Hematology & Oncology, 2012
Background Therapy-related myeloid neoplasms (t-MN), including myelodysplastic syndromes and acute myeloid leukemia (t-MDS and t-AML) are associated to clinical and biologic unfavorable prognostic features, including high levels of DNA methylation ...
Fianchi Luana, Criscuolo Marianna, Lunghi Monia, Gaidano Gianluca, Breccia Massimo, Levis Alessandro, Finelli Carlo, Santini Valeria, Musto Pellegrino, Oliva Esther N, Leoni Pietro, Spiriti Antonietta, D’Alò Francesco, Hohaus Stefan, Pagano Livio, Leone Giuseppe, Voso Maria   +16 more
doaj   +1 more source

Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS)

Case Reports in Hematology, 2020
T/myeloid mixed-phenotype acute leukemia not otherwise specified (MPAL NOS) is an uncommon and aggressive leukemia without well-established treatment guidelines, particularly when relapsed.
Heather Klocke, Zhao Ming Dong, Craig O’Brien, Nicholas Burwick, Robert E. Richard, Daniel Y. Wu, Thomas R. Chauncey, Solomon A. Graf   +7 more
doaj   +1 more source

IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells [PDF]

, 2018
In high-grade serous ovarian cancer (OC), chemotherapy eliminates the majority of tumor cells, leaving behind residual tumors enriched in OC stem cells (OCSC).
Berek, Canino, Fang, Han, Kastan, Paschall, Pasquier, Wang, Wang, Zou, Ørskov   +10 more
core   +1 more source

The Functional Role and Molecular Characterization of the Therapeutic Target CLDN6 in Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick, Margaretha A. Skowron, Gereon Poschmann, Patrick Petzsch, Ann Kathrin Bergmann, Kai Stühler, Jochen Hecht, Daniel Nettersheim   +7 more
wiley   +1 more source

RSL3 enhances ROS-mediated cell apoptosis of myelodysplastic syndrome cells through MYB/Bcl-2 signaling pathway

Cell Death and Disease
Myelodysplastic syndromes (MDS) are clonal hematopoietic malignancies and seriously threaten people’s health. Current therapies include bone marrow transplantation and several hypomethylating agents.
Li Liu, Chaoying Yang, Lin Zhu, Yanyan Wang, Fuxiang Zheng, Long Liang, Pengfei Cao, Jing Liu, Xu Han, Ji Zhang   +9 more
doaj   +1 more source

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors

Chinese Medical Journal, 2020
. Epigenetic regulation includes changes of DNA methylation and modifications of histone proteins and is essential for normal physiologic functions, especially for controlling gene expression.
Qing-Yu Xu, Li Yu, Peng Lyu
doaj   +1 more source

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer [PDF]

, 2009
DNA methylation and histone acetylation are two well known epigenetic chromatin modifications. Epigenetic agents leading to DNA hypomethylation and histone hyperacetylation have been approved for treatment of hematological disorders.
Shundong Cang, Yuehua Ma, Delong Liu
core   +1 more source

Clonal haematopoiesis in T‐follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution

British Journal of Haematology, EarlyView.
Summary T‐follicular helper cell lymphomas (TFHLs) are frequently associated with epigenetic mutations and clonal haematopoiesis (CH), but the clinical and prognostic implications of CH in TFHL remains unclear. We performed next‐generation sequencing on paired peripheral blood (PB) and tumour tissue samples from 30 patients with TFHL. CH was defined by
Chong Wei, Yan Zhang, Danqing Zhao, Wei Zhang, Daobin Zhou   +4 more
wiley   +1 more source

Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting

Cancer Management and Research, 2021
Juan Tong, Na Zhao, Xing Hu, Wen Yao, Yaxin Cheng, Li Zhou, Huilan Liu, Liangquan Geng, Zimin Sun, Changcheng Zheng Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and ...
Tong J, Zhao N, Hu X, Yao W, Cheng Y, Zhou L, Liu H, Geng L, Sun Z, Zheng C   +9 more
doaj